Replaces Prod. #: ALX-270-303
Weak histone deacetylase (HDAC) inhibitor. Induces differentiation, growth arrest and apoptosis in a number of cell lines. Protects against cerebral ischemic injury and displays neuroprotective effect in a mouse model of Huntington’s disease. Anti-neoplastic agent and transcriptional regulator. Also acts as an inducer of tumor cytostasis and differentiation. Shows chemical chaperone activity.
Product Details
Alternative Name: | Sodium 4-phenylbutyrate, 4-Phenylbutyric acid sodium salt, SBP, 4PBA, PBNa |
|
Formula: | C10H11O2 . Na |
|
MW: | 186.2 |
|
CAS: | 1716-12-7 |
|
Purity: | ≥98% (UHPLC) |
|
Appearance: | White to yellowish solid. |
|
Solubility: | Soluble in DMSO or water (25mg/ml). |
|
Shipping: | Ambient |
|
Long Term Storage: | Ambient |
|
Use/Stability: | Stable for at least 1 year after receipt when stored at +20°C. Stock solutions are stable for up to 3 months at -20°C. |
|
Handling: | Hygroscopic. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Phenylbutyrate - a pan-HDAC inhibitor - suppresses proliferation of glioblastoma LN-229 cell line: M. Kuszaczuk, et al.; Tumour Biol.
37, 931 (2016),
Application(s): Cell culture,
Abstract;
Full Text
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells: K. Huber, et al.; J. Biol. Chem.
286, 22211 (2011),
Abstract;
Full Text
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease: G. Gardian, et al.; J. Biol. Chem.
280, 556 (2005),
Abstract;
Full Text
Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells: I.B. Appelskog, et al.; Int. J. Oncol.
24, 1419 (2004),
Abstract;
Sodium 4-phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway: X. Zhang, et al.; J. Cell. Biochem.
93, 819 (2004),
Abstract;
Sodium 4-phenylbutyrate protects against cerebral ischemic injury: X. Qi, et al.; Mol. Pharmacol.
66, 899 (2004),
Abstract;
Full Text
Butyrate as a model for "gene-regulating chemoprevention and chemotherapy.": Y. Sowa & T. Sakai; Biofactors
12, 283 (2000),
Abstract;
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors: S.D. Gore & M.A. Carducci; Expert Opin. Investig. Drugs
9, 2923 (2000),
Abstract;
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase: R.P. Warrell, et al.; J. Natl. Cancer Inst.
90, 1621 (1998),
Abstract;
Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase: M.A. Lea & N. Tulsyan; Anticancer Res.
15, 879 (1995),
Abstract;